{"ModuleTitle": "Company Description", "CompanyName": "aTyr Pharma, Inc.", "Symbol": "LIFE", "Address": "3545 JOHN HOPKINS COURT, STE #250, SAN DIEGO, California, 92121, United States of America", "Phone": "858-731-8389", "Industry": "Biotechnology: Biological Products (No Diagnostic Substances)", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "We are a biotherapeutics company engaged in the discovery and development of\r\ninnovative medicines based on novel immunological pathways. We have concentrated\r\nour research and development efforts on a newly discovered area of biology, the\r\nextracellular functionality and signaling pathways of tRNA synthetases. Built on\r\nmore than a decade of foundational science on extracellular tRNA synthetase\r\nbiology and its effect on immune responses, we have built a global intellectual\r\nproperty estate directed to a potential pipeline of protein compositions derived\r\nfrom 20 tRNA synthetase genes and their extracellular targets, such as\r\nneuropilin-2 (NRP2).\r\n\r\nOur primary focus is on ATYR1923, a clinical stage product candidate which binds\r\nto the NRP2 receptor and is designed to down regulate immune engagement in\r\ninterstitial lung diseases (ILDs).&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f03%2f26%2f0001564590-20-013208.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Jill M. Broadfoot", "title": "Chief Financial & Accounting Officer"}, {"name": "Sanjay S. Shukla", "title": "President, Chief Executive Officer & Director"}], "Number_of_employees": [], "Subsidiaries": ["NO INFO"]}